Alnylam Pharmaceuticals (ALNY) Common Equity (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Common Equity for 18 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 143.83% year-over-year to $1.4 billion; the trailing twelve-month figure through Jun 2026 stood at $1.4 billion (up 143.83% YoY), and the FY2025 full-year result was $789.2 million, up 1076.33% from the prior year.
• Common Equity climbed to $1.4 billion in Q2 2026 per ALNY's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.4 billion in Q2 2026 and bottomed at -$408.1 million in Q2 2023.
• Historically, Common Equity has averaged $200.5 million across 5 years, with a median of $49.7 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Common Equity sank 331.84% in 2023, then jumped 18207.11% in 2025.
• Over 5 years, Common Equity stood at -$158.2 million in 2022, then plunged by 39.45% to -$220.6 million in 2023, then jumped by 130.41% to $67.1 million in 2024, then soared by 1076.33% to $789.2 million in 2025, then jumped by 71.59% to $1.4 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $1.4 billion, $1.1 billion, and $789.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.